2020-12-14

Camurus announces outcome of the arbitration process with Braeburn.

Camurus announced on December 10, 2020, that the ICC International Court of Arbitration has issued a partial award in the arbitration process between Camurus and Braeburn regarding the parties’ license agreement for the development and commercialization of CAM2038 in North America.

Read the full press release on Camurus' website: https://www.camurus.com/

Latest news

2018-12-07

Buvidal® Weekly and Buvidal® Monthly (CAM2038) approved in Australia as the first long-acting treatment of opioid dependence

Camurus announced today that the Australian Therapeutic Goods Administration (TGA) has approved the company’s lead p…

Read more

2018-11-22

Camurus receives EU approval for Buvidal®

Camurus receives EU approval for weekly and monthly Buvidal® (CAM2038) for opioid dependence. Buvidal® is the first…

Read more

2018-10-26

AF Bostäder has installed SWATAB's filter system

AF Bostäder in Lund will open two new laundry rooms at Vildanden, a student housing, where the students can wash wit…

Read more

2018-10-26

Camurus Interim Report January-September 2018

“Following the positive CHMP opinion for Buvidal®, we have ramped up our commercial activities and are ready for lau…

Read more

2018-07-20

Solo Rescue to spin-off from GRANULDISK

Sandberg Development has decided to spin-off and concentrate the business within the subsidiary GRANULDISK’s product…

Read more